Company: CERO
Filing Date: 2025-06-30
Form Type: 8-K
Source: 0001213900-25-059738
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-06-30
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01

Entry into Material Definitive Agreement.

On June 25, 2025, CERo Therapeutics Holdings,
Inc. (the “ Company”) entered into an amendment (the “ Amendment”) to the securities purchase agreement (as amended,
the “ Securities Purchase Agreement”) dated as of April 21, 2025, pursuant to which the Company added certain new institutional
investors (the “ New Investors”) to the schedule of buyers in the Securities Purchase Agreement, to issue and sell to such
New Investors, in one or more closings shares of the Company’s Series D convertible preferred stock, par value $0.0001 per share
(the “ Series D Preferred Stock”).

The description of the terms and conditions of the Amendment does not
purport to be complete and is qualified in its entirety by the full text of the form of Amendment, which is filed as Exhibit 10.2 hereto.

Item 3.02Unregistered Sales of Equity Securities.